GO
Loading...

Enter multiple symbols separated by commas

GlaxoSmithKline PLC

More

  • Early movers: GEVA, MGI, JPM, WEN, NWSA & more Wednesday, 6 May 2015 | 7:51 AM ET
    A trader works on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • Chief Executive Andrew Witty is under pressure to prove to investors that a $20 billion- plus asset swap with Novartis can revive GSK's fortunes, following a damaging slide in lung drug sales and a major corruption scandal in China. In a bid to protect its dividend, GSK scaled back plans to return 4 billion pounds of cash flowing from the Novartis transaction to...

  • INTERVIEW-New-look GSK bets on consumer health spending Wednesday, 6 May 2015 | 7:19 AM ET

    LONDON, May 6- Consumers from New York to New Delhi are digging deeper in their pockets for over-the-counter remedies and health products, a trend GlaxoSmithKline is banking on to help shape the next chapter in its evolution. In the biggest shake-up in its 15- year history, GSK has just sold its cancer drugs to Novartis, while buying the Swiss group's vaccine...

  • LONDON, May 6- GlaxoSmithKline laid out growth targets for its biggest businesses on Wednesday, hoping to convince investors that focusing on consumer health and vaccines would return the drugmaker to long-term growth. Chief Executive Andrew Witty is under pressure to prove to investors that a $20 billion- plus asset swap with Novartis can revive GSK's...

  • Higher yields sting stocks as jobs take center stage Wednesday, 6 May 2015 | 5:57 AM ET
    Traders work on the floor of the New York Stock Exchange (NYSE)

    Payroll data will be key for bonds, stocks and the dollar, and it could set the stage for a bigger markets move when jobs report number is released.

  • Higher rates sting stocks; markets await job data Tuesday, 5 May 2015 | 7:11 PM ET
    Traders work on the floor of the New York Stock Exchange (NYSE)

    Payroll data will be key for bonds, stocks and the dollar, and it could set the stage for a bigger markets move when jobs report number is released.

  • What matters to markets this week Monday, 4 May 2015 | 6:00 AM ET
    Traders work on the floor of the New York Stock Exchange (NYSE)

    Influences from abroad may first drive stocks, bonds and the dollar.

  • Siemens unit in China bribery probe - report Sunday, 3 May 2015 | 5:42 AM ET
  • The investigation, which has not previously been reported, follows a wide-reaching probe into the pharmaceutical industry in China that last year saw GlaxoSmithKline Plc fined nearly $500 million for bribing officials to push its medicine sales. "We are not aware of any situation that conforms to what you describe," said Germany- based spokesman Matthias...

  • Jobs report is big but watch out for Europe Friday, 1 May 2015 | 7:21 PM ET
    Traders work on the floor of the New York Stock Exchange (NYSE)

    Influences from abroad may first drive stocks, bonds and the dollar.

  • *Cash return was planned after Novartis asset swap deal. Instead, Britain's biggest drugmaker could use cash flowing in from its far-reaching asset swap deal with Novartis to support its dividend, according to analysts at Goldman Sachs and Berenberg Bank. GSK said last year it intended to return 4 billion pounds to shareholders in 2015 through a so-called B...

  • LONDON, April 28- An experimental shingles vaccine from GlaxoSmithKline is effective across all age groups, researchers said on Tuesday, boosting the prospects of a key product in the British drugmaker's development pipeline. Goldman Sachs analysts said in a report on Tuesday that efficacy across age groups could give HZ/su a meaningful edge over Zostavax,...

  • *Celladon trial failure shows field remains high-risk. LONDON, April 27- GlaxoSmithKline is close to seeking European approval for a gene therapy drug to fight the immune deficiency disorder known as "bubble boy" disease, in the latest sign of a renaissance in the technology to fix faulty genes. Gene therapy last year won $3.0 billion of financing, up 510 percent on...

  • Tekmira Ebola drug succeeds in small monkey study Wednesday, 22 Apr 2015 | 1:00 PM ET

    NEW YORK, April 22- An experimental Ebola drug from Tekmira Pharmaceuticals Corp cured all three monkeys intentionally infected with the virus, scientists reported on Wednesday, the first such success against the strain of Ebola in West Africa's 2014-2015 outbreak. Although other experimental treatments appeared to help Ebola patients last year,...

  • *Global nutraceutical market seen at $280 bln by 2018. LONDON, April 21- A boom in "nutraceuticals"- food and drinks with potential health benefits- is paving the way for a rush of deals, as food and drug companies compete to dominate a market expected to be worth $280 billion by 2018.. "The space is ripe for M&A and I think you are going to see more," added Jeremy Johnson,...

  • This country is becoming a force in 'fintech' Friday, 17 Apr 2015 | 2:34 AM ET
    London's Old Street roundabout, dubbed "Silicon Roundabout"

    Investment in technology that provides financial services has more than tripled in the region, giving its economy a much-needed boost.

  • *Index Ventures clocks up 11 transactions since 2005. Ten years on from pioneering an ultra-lean business model focused on investing in "virtual" companies with a single experimental medicine, XO1's backer Index Ventures is chalking up some notable wins. The new model has grabbed attention as venture capitalists strive to improve returns in a notoriously...

  • Biotech wins $45 million grant for Ebola vaccine Monday, 6 Apr 2015 | 9:28 AM ET
    Dr. Joseph Kim, founder of Inovio Pharmaceuticals

    Today's vaccine debate will be outdated if Inovio succeeds in developing DNA vaccines. Imagine a single needle shot that can cure Ebola.

  • An outbreak of Ebola killed close to 10,000 people across West Africa over the last year, with Liberia, Guinea and Sierra Leone being the worst affected. Private company Mapp Biopharmaceutical and Tekmira Pharmaceuticals Corp have shown that their Ebola drugs could cure non-human primates. The other companies that are currently testing potential...

  • Early movers: MRH, JCI, DHI, PHG, TEVA, CVC & more Tuesday, 31 Mar 2015 | 7:51 AM ET
    A trader works on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.